Please assess the completion status of the following clinical trial:

Trial Title: Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18 Years to 70 Years~* Performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) Scale.~* Previously untreated, histological documented, inoperable stage III squamous cell carcinoma of lung, excluding those with pericardial, pleural effusion, and those with contralateral hilar or contralateral supraclavicular lymph nodes.~* Patients must have measurable disease according to RECIST criteria, and all detectable tumor can be encompassed by radiation therapy fields.~* Patient must have adequate blood, liver, lungs and kidney function within the requirements of this study.~* Female patients of child-bearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test. Male and female patients must agree to use a reliable method of birth control during and for 3 months following the last dose of study drug.~* Patients must sign a study-specific informed consent form prior to study entry.~Exclusion Criteria:~* Complete tumor resection, recurrent disease, or those patients eligible for definitive surgery.~* Previous chemotherapy or previous biologic response modifiers for current lung cancer.~* Patient has previously had thoracic radiation therapy.~* Prior or concurrent malignancy except non-melanomatous skin cancer unless disease-free for five years or more.~* Serious concomitant disorders that would compromise the safety of the patient, or compromise the patient's ability to complete the study, at the discretion of the investigator.~* History of significant neurological or mental disorder, including seizures or dementia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Nab-paclitaxel (Type: EXPERIMENTAL): Nab-paclitaxel and carboplatin for Injection; thoracic radiation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).